Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Meridian Bioscience (VIVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Meridian Bioscience (VIVO) closed at $24.49 in the latest trading session, marking a -1.84% move from the prior day.
Meridian Bioscience (VIVO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Meridian Bioscience (VIVO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VIVO) Outperforming Other Medical Stocks This Year?
Chembio Diagnostics (CEMI) Surges: Stock Moves 12.1% Higher
by Zacks Equity Research
Chembio Diagnostics (CEMI) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
BioLife (BLFS) Catches Eye: Stock Jumps 12.1%
by Zacks Equity Research
BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy
Exagen (XGN) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
by Zacks Equity Research
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
5 Stocks to Wade Through Hurdles in Second-Half 2020
by Sreoshi Bera
Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.
5 Stocks With Recent Price Strength Amid Spike in Coronavirus
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
New Strong Buy Stocks for June 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Meridian Bioscience (VIVO) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Meridian Bioscience (VIVO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Picks for Week of May 11, 2020
by Panel Of Zacks Experts
Two Medical Products Stocks with Recent Price Strength.
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 187.50% and 0.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 66.67% and -2.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 44.44% and 1.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Pick Meridian Bioscience (VIVO) Now?
by Zacks Equity Research
Let's see if Meridian Bioscience (VIVO) stock is a good choice for value-oriented investors right now from multiple angles.
Meridian Bioscience (VIVO) Beats Q3 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 60.00% and -2.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.